Artikel ; Online: Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Nature reviews. Clinical oncology
2021 Band 18, Heft 8, Seite(n) 527–540
Abstract: Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate ... ...
Abstract | Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate antitumour immunity owing to the inhibition of various immunosuppressive features of angiogenesis. Hence, combinations of anti-angiogenic agents and immunotherapy are currently being tested in >90 clinical trials and 5 such combinations have been approved by the FDA in the past few years. In this Perspective, we describe how the angiogenesis-induced endothelial immune cell barrier hampers antitumour immunity and the role of endothelial cell anergy as the vascular counterpart of immune checkpoints. We review the antitumour immunity-promoting effects of anti-angiogenic agents and provide an update on the current clinical successes achieved when these agents are combined with immune checkpoint inhibitors. Finally, we propose that anti-angiogenic agents are immunotherapies - and vice versa - and discuss future research priorities. |
---|---|
Mesh-Begriff(e) | Angiogenesis Inhibitors/therapeutic use ; Animals ; Clonal Anergy/drug effects ; Combined Modality Therapy ; Drug Resistance, Neoplasm/immunology ; Humans ; Immunotherapy/methods ; Immunotherapy/trends ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/pathology ; Neoplasms/therapy ; Treatment Outcome ; Tumor Escape/drug effects ; Tumor Escape/physiology ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology |
Chemische Substanzen | Angiogenesis Inhibitors |
Sprache | Englisch |
Erscheinungsdatum | 2021-04-08 |
Erscheinungsland | England |
Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 2491410-1 |
ISSN | 1759-4782 ; 1759-4774 |
ISSN (online) | 1759-4782 |
ISSN | 1759-4774 |
DOI | 10.1038/s41571-021-00496-y |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 6029: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MG 103: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.